This company has been marked as potentially delisted and may not be actively trading. Immuron (IMRN) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsHeadlinesShort InterestTrendsBuy This Stock IMRN vs. HOWL, FBIO, MRSN, MIST, ITRM, PRLD, RPTX, CELU, VRCA, and IBIOShould you be buying Immuron stock or one of its competitors? The main competitors of Immuron include Werewolf Therapeutics (HOWL), Fortress Biotech (FBIO), Mersana Therapeutics (MRSN), Milestone Pharmaceuticals (MIST), Iterum Therapeutics (ITRM), Prelude Therapeutics (PRLD), Repare Therapeutics (RPTX), Celularity (CELU), Verrica Pharmaceuticals (VRCA), and iBio (IBIO). These companies are all part of the "pharmaceutical preparations" industry. Immuron vs. Werewolf Therapeutics Fortress Biotech Mersana Therapeutics Milestone Pharmaceuticals Iterum Therapeutics Prelude Therapeutics Repare Therapeutics Celularity Verrica Pharmaceuticals iBio Immuron (NASDAQ:IMRN) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings. Does the MarketBeat Community favor IMRN or HOWL? Immuron received 154 more outperform votes than Werewolf Therapeutics when rated by MarketBeat users. However, 70.83% of users gave Werewolf Therapeutics an outperform vote while only 67.87% of users gave Immuron an outperform vote. CompanyUnderperformOutperformImmuronOutperform Votes18867.87% Underperform Votes8932.13% Werewolf TherapeuticsOutperform Votes3470.83% Underperform Votes1429.17% Is IMRN or HOWL more profitable? Immuron has a net margin of 0.00% compared to Werewolf Therapeutics' net margin of -578.80%. Immuron's return on equity of 0.00% beat Werewolf Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ImmuronN/A N/A N/A Werewolf Therapeutics -578.80%-58.83%-38.45% Do analysts recommend IMRN or HOWL? Immuron currently has a consensus target price of $5.00, suggesting a potential upside of 184.74%. Werewolf Therapeutics has a consensus target price of $9.00, suggesting a potential upside of 1,328.57%. Given Werewolf Therapeutics' higher probable upside, analysts plainly believe Werewolf Therapeutics is more favorable than Immuron.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immuron 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Werewolf Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders have more ownership in IMRN or HOWL? 0.1% of Immuron shares are owned by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are owned by institutional investors. 7.0% of Immuron shares are owned by insiders. Comparatively, 21.1% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, IMRN or HOWL? Immuron has a beta of 1.38, indicating that its stock price is 38% more volatile than the S&P 500. Comparatively, Werewolf Therapeutics has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Which has preferable valuation and earnings, IMRN or HOWL? Immuron has higher revenue and earnings than Werewolf Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmuron$3.21M3.19-$4.55MN/AN/AWerewolf Therapeutics$1.89M14.98-$37.37M-$1.66-0.38 Does the media favor IMRN or HOWL? In the previous week, Immuron's average media sentiment score of 0.00 equaled Werewolf Therapeutics'average media sentiment score. Company Overall Sentiment Immuron Neutral Werewolf Therapeutics Neutral SummaryImmuron beats Werewolf Therapeutics on 7 of the 13 factors compared between the two stocks. Remove Ads Get Immuron News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMRN vs. The Competition Export to ExcelMetricImmuronPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.03M$6.22B$5.16B$7.06BDividend YieldN/A2.87%5.00%4.18%P/E RatioN/A6.7720.7917.35Price / Sales3.19193.40360.0189.12Price / CashN/A65.6738.1534.64Price / Book1.205.506.153.76Net Income-$4.55M$141.14M$3.19B$247.27M Immuron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMRNImmuron1.8834 of 5 stars$1.76-12.2%$5.00+184.7%N/A$11.03M$3.21M0.00N/AHOWLWerewolf Therapeutics1.7453 of 5 stars$0.97-5.6%$9.00+825.7%-88.2%$43.58M$1.89M-0.6440Gap DownFBIOFortress Biotech2.3607 of 5 stars$1.56-3.1%$21.00+1,246.2%-18.7%$43.06M$62.50M-0.51170Earnings ReportAnalyst RevisionGap DownMRSNMersana Therapeutics4.2517 of 5 stars$0.34-9.3%$4.00+1,062.1%-92.9%$42.90M$40.50M-0.56150Gap DownMISTMilestone Pharmaceuticals1.6679 of 5 stars$0.80-9.1%$17.00+2,025.0%-61.4%$42.68M$1M-0.9930Analyst RevisionGap DownHigh Trading VolumeITRMIterum Therapeutics1.5938 of 5 stars$1.23-2.4%$5.00+306.5%-35.8%$42.54MN/A-0.9410Gap DownPRLDPrelude Therapeutics2.2723 of 5 stars$0.77-3.7%$4.00+419.5%-85.6%$42.47M$7M-0.43120Gap DownHigh Trading VolumeRPTXRepare Therapeutics2.7639 of 5 stars$0.99-6.1%$4.50+356.4%-74.9%$41.91M$53.48M-0.49180Gap DownCELUCelularityN/A$1.73-2.4%N/A-74.1%$41.19M$48.20M0.00220VRCAVerrica Pharmaceuticals3.6397 of 5 stars$0.44+2.1%$9.50+2,048.3%-92.1%$40.59M$7.57M-0.2440IBIOiBio1.0715 of 5 stars$4.02-2.4%$4.30+7.0%+52.6%$39.70M$375,000.000.00100News CoverageGap Down Remove Ads Related Companies and Tools Related Companies HOWL Competitors FBIO Competitors MRSN Competitors MIST Competitors ITRM Competitors PRLD Competitors RPTX Competitors CELU Competitors VRCA Competitors IBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMRN) was last updated on 4/7/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuron Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMRN Stock Free IMRN Stock Alerts